Jupiter Life Line Hospitals Limited (NSE:JLHL)
India
· Delayed Price · Currency is INR | Market Cap | 82.06B |
| Revenue (ttm) | 14.08B |
| Net Income (ttm) | 1.89B |
| Shares Out | 65.57M |
| EPS (ttm) | 28.86 |
| PE Ratio | 43.36 |
| Forward PE | 39.32 |
| Dividend | 1.00 (0.08%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 53,293 |
| Average Volume | 25,476 |
| Open | 1,243.80 |
| Previous Close | 1,251.50 |
| Day's Range | 1,234.00 - 1,254.40 |
| 52-Week Range | 1,178.00 - 1,625.00 |
| Beta | 0.32 |
| RSI | 44.32 |
| Earnings Date | May 8, 2026 |
About NSE:JLHL
Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurger... [Read more]
Financial Performance
In fiscal year 2025, NSE:JLHL's revenue was 12.62 billion, an increase of 17.52% compared to the previous year's 10.73 billion. Earnings were 1.94 billion, an increase of 9.56%.
Financial StatementsNews
Jupiter Life Line Hospitals Transcript: Q3 25/26
Q3 FY2026 saw 9.8% revenue growth and 9.2% EBITDA growth, but PAT declined 18.7% due to a one-time labor code provision. The new Dombivli hospital will initially weigh on margins, while mature hospitals maintain stable performance.
Jupiter Life Line Hospitals Transcript: Q2 25/26
Q2 and H1 FY26 saw double-digit revenue and EBITDA growth, with strong ARPOB gains and ongoing hospital expansion. Margin dilution is expected as new hospitals come online, but long-term demand remains robust. Unbilled revenue and one-off provisions impacted reported results.
Jupiter Life Line Hospitals Transcript: Q1 25/26
Q1 FY26 saw 20.5% revenue growth and 19.6% EBITDA growth, but PAT declined 1.6% due to higher depreciation and finance costs. Occupancy and patient volumes rose, with strong ARPOB growth from price hikes and case mix. Renewable energy investments and greenfield expansions continue.
Jupiter Life Line Hospitals Transcript: Q4 24/25
Q4 income rose 12.1% year-on-year to INR 326.7 crores, with EBITDA margin at 23.9% and PAT margin at 13.7%. Expansion continues with new beds, greenfield projects, and prudent debt, while ARPOB growth is expected to align with inflation.
Jupiter Life Line Hospitals Transcript: Q3 24/25
Q3 FY25 saw 17.7% YOY revenue growth and 21.5% EBITDA growth, with strong margins and robust expansion plans. New hospitals in Mira Road, Pune, and Dombivli are on track, funded by internal accruals, with no additional debt planned.
Jupiter Life Line Hospitals Transcript: Q2 24/25
Q2 and H1 FY25 saw strong revenue and profit growth, with expanding margins and occupancy rates. Major CapEx is focused on new greenfield hospitals in Dombivli and Pune, while Indore and Pune continue to add capacity. Regulatory delays and expansion may temporarily impact occupancy metrics.
Jupiter Life Line Hospitals Transcript: Q1 24/25
Q1 FY2025 saw 18.2% revenue growth and 20.9% EBITDA growth year-over-year, with strong occupancy gains in Pune and Indore. Expansion is on track, with new beds added and further projects underway, while margins are expected to reach 25% as hospitals mature.